|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Aberrant methylation of the DCC gene was detected in 16 out of the 36 (44%) primary gastric carcinomas.
|
20150623 |
2010 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The methylation status of the UNC5C and DCC genes were examined in primary carcinomas and the corresponding normal tissues derived from 50 patients with colorectal cancer using quantitative methylation-specific polymerase chain reaction (qMSP).
|
19242752 |
2009 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of DCC mRNA expression is found in 50% of serous carcinomas but less frequently in other type.
|
12770737 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
According to this hypothesis, we investigated the p53 and the DCC proteins expression in different stages of gastric carcinomas.
|
11518545 |
2001 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, 13.8% of ovarian, 8.3% of colon and 22% of lung carcinomas exhibited LOH for NER factors without LOH for tumor suppressor genes such as p53, FHIT, APC, BRCAI, BRCA2 and DCC.
|
11689286 |
2001 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To correlate the length of the telomere to microsatellite instability (MSI) and loss of heterozygosity (LOH) of APC, MCC and DCC genes in gastric carcinomas.
|
11819821 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Significantly decreased levels of overall DCC values in carcinomas compared with benign and LMP lesions were revealed by both immunohistochemical and RT-PCR/SBH assays.
|
10682668 |
2000 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A series of molecular changes including loss of heterozygosity (LOH) at 17p (TP53 gene), 13q (RB gene), 18q (DCC gene), and 9p21 (CDKN2a gene) chromosomal regions have been identified in dysplasias, carcinomas in situ, and invasive carcinomas of the gallbladder, whereas mutations in K- and N-ras genes are rare.
|
9923922 |
1999 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To elucidate further genetic alterations in flat-type colorectal tumors, codon 201Arg/Gly polymorphism in the DCC (deleted in colorectal carcinoma) gene was analyzed in normal tissue (normal colonic mucosa or peripheral lymphocytes) and in tumor tissue from 191 patients with colorectal tumors (36 patients with flat-type colorectal tumors, 81 patients with polypoid-type colorectal tumors, and 74 patients with advanced carcinomas).
|
9440618 |
1997 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In order to clarify the association between bcl-2 protein (Bcl-2) expression and genetic alteration, we investigated p53 and DCC (deleted in the colon carcinoma gene locus) gene abnormalities in Bcl-2-positive and -negative gastric carcinomas using a polymerase chain reaction/loss of heterozygosity (LOH) assay.
|
8690754 |
1996 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Alterations of the p53 and DCC genes occurred frequently both in differentiated and in undifferentiated gastric carcinomas.
|
7674088 |
1995 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
While histologically normal endometrium, cervical epithelium and ovary expressed detectable mRNA of the DCC gene, three of eight (37%) endometrial carcinomas, one of two (50%) cervical carcinomas and 9 of 22 (41%) ovarian malignant tumours had significantly reduced or negligible DCC expression, and another endometrial carcinoma and two other ovarian tumors underexpressed DCC when compared with histologically normal endometrial or ovarian tissues.
|
7880725 |
1995 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the present study, we examined 51 cases of primary esophageal carcinomas with regard to point mutations and loss of the DCC gene.
|
8187090 |
1994 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DCC expression was not observed in any of five hepatic metastasis or in five of seven advanced carcinomas that were accompanied by hepatic metastasis (10 of 12).
|
7906606 |
1994 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas.
|
8504411 |
1993 |